Delving into the Latest Updates on Pemefolacianine with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

NY-FR-007

Target

FOLR1

Action

modulators

Mechanism

FOLR1 modulators(Folate receptor alpha modulators)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases+ [1]

Active Indication

Ovarian CancerContrast agents

Inactive Indication-

Originator Organization

Nanjing Nuoyuan Medical Devices Co., Ltd.

Active Organization

Nanjing Nuoyuan Medical Devices Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

To evaluate the efficacy of a single intravenous dose of cytoreductive green for injection for tumor visualization in patients scheduled for cytoreductive surgery for ovarian cancer. To assess the safety, pharmacokinetics, and pharmacodynamics of cytoreductive green for injection in patients with ovarian cancer.

Start Date-

Sponsor / Collaborator

Nanjing Nuoyuan Medical Devices Co., Ltd.

100 Clinical Results associated with Pemefolacianine

Login to view more data

100 Translational Medicine associated with Pemefolacianine

Login to view more data

100 Patents (Medical) associated with Pemefolacianine

Login to view more data

100 Deals associated with Pemefolacianine

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Cancer	Phase 2	China	Nanjing Nuoyuan Medical Devices Co., Ltd.	05 Aug 2025
Contrast agents	IND Approval	United States	Nanjing Nuoyuan Medical Devices Co., Ltd.	31 Dec 2024